|
Baseline characteristics of patients with early inflammatory arthritis of non-crystal origin |
||||
| RA |
Non-RA persistent |
Resolving |
P |
|
|
|
||||
| Number |
8 |
14 |
14 |
|
| Female (n) |
4 |
6 |
6 |
NSa |
| Age (years)b,c |
65.5 (55–73) |
29.5 (23.5–61) |
28.5 (21–45) |
0.006d RA versus non-RA persistent <0.05e RA versus resolving <0.01e |
| Symptom duration (weeks)b,c |
9 (6–9.5) |
7.5 (2.5–11.5) |
4 (2–8) |
NSd |
| CRP (mg/l)b,c |
31 (27.5–52.5) |
67 (29–172.5) |
24 (3.5–45) |
NSd |
| RF ≥30 IU/ml (n) |
7 |
0 |
2 |
<0.0001a |
| Anti-CCP antibodies ≥5 IU/ml (n) |
7 |
0 |
1 |
<0.0001a |
| RF ≥30 IU/ml + Anti-CCP antibodies ≥5 IU/ml (n) |
7 |
0 |
0 |
<0.0001a |
| Initial NSAID use (n) |
7 |
6 |
8 |
NSa |
| Initial DMARD use (n) |
0 |
0 |
0 |
NSa |
| Initial prednisolone use (n) |
0 |
3 |
0 |
NSa |
| Joint aspirated (knee/ankle [n]) |
5/3 |
13/1 |
11/3 |
NSa |
|
aχ2 test. bMedian. cInterquartile range. dKruskall–Wallis test. eWhere the medians were significantly different at the 5% level, Dunn's post-test was used to compare individual groups. CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; NS, not significant; NSAID, nonsteroidal antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor. | ||||
Raza et al. Arthritis Research & Therapy 2005 7:R784 doi:10.1186/ar1733 |
||||